Assessing biomarkers in synovial fluid: consider the kinetics of clearance  by Simkin, P.A.
Osteoarthritis and Cartilage 21 (2013) 7–9Editorial
Assessing biomarkers in synovial ﬂuid: consider the kinetics of clearanceKeywords:
Biomarkers
Kinetics
Synovial ﬂuid
Clearance1063-4584/$ – see front matter  2012 Osteoarthritis
http://dx.doi.org/10.1016/j.joca.2012.09.015a The range of molecular radii betweenw2 nm andw10 nm encompasses almost
all plasma proteins, but some biomarkers of interest do not fall within it. For
instance, hyaluronan and some larger and/or more linear fragments of aggrecan
appear to encounter steric hindrance en route to the terminal lymphatics and
will be cleared more slowly. Conversely, cytokines of interest are small and they
may be consumed within the joint space and/or diffuse into the bloodstream
through the microvascular fenestrae. Both of these mechanisms will accelerate
cytokine clearance from SF.Beyond question, the synovial ﬂuid (SF) of every arthritic joint
contains mediators of the inﬂammatory response and products of
the attendant injury to articular tissues. With the availability of
the powerful tools of modern proteomics, such molecules generate
intense interest as potential biomarkers that may be quantiﬁed in
SF and used to enhance understanding of pathophysiology and
evaluate management of inﬂammation in people with arthritis.
But, such potential biomarkers do not travel alone. They enter the
SF in company with a host of plasma proteins which complicate
the assays as they admix with the markers of interest. However,
the subsequent clearance of all solutes, both intrinsic (from carti-
lage) and extrinsic (from plasma), is governed by the same shared
principles and pathways. This editorial uses lessons learned from
studies of plasma protein kinetics in SF to describe a quantitative,
kinetic approach to the problems and opportunities encountered
in biomarker work.
For the most part, biomarker interest focuses on comparisons.
Does a speciﬁcmarker differentiate betweenpatients or conditions?
Or does amarker change for better or for worse as a joint of concern
is followedover time? For bothof these questions,what the clinician
would like most to know is the rate of production or release in, for
instance, mg/min. Unfortunately, such rates are virtually never
available. Instead, the accessible parameter is concentration and
concentrations can be misleading. Rheumatologists have long
known that the total SF protein concentration, aswell as the concen-
tration ofmost individual plasma proteins, holds little or no value in
the diagnosis or management of arthritis1,2. There is awide range of
ﬁndings within every group of patients with any given diagnosis. In
part this range must reﬂect the inevitable variation in disease
severity, duration, and response to previous therapy that occur
within any such panel. In addition, however, it appears that as
trans-endothelial escape of plasma proteins increases, synovial
lymphatic outﬂow tends to rise in a roughly parallel fashion that
leaves the concentration at similar levels despite unequivocal differ-
ences in the rate of input. This wide variation in rates of SF clearance
poses major problems for students of articular biomarkers.
The concentration in SF depends on the balance between input
and output (clearance), and these factors are equal partners. The
same concentration in two different effusions does not imply equalResearch Society International. Puinputs unless it is known that their clearances are also the same.
This truism pertains even when the data are derived from the same
joint on two different occasions. For instance, consider a biomarker
that is found to have the samemean concentration in groups of rheu-
matoid (RA) and osteoarthritic (OA) patients. The average RA knee
has been found to clear protein essentially twice as fast as does the
average OA knee3,4. Therefore, the marker release in this example
is probably twice as great in the RA as it is in the OA knee despite
the identical concentration. Conversely, an OA concentration twice
that found in RAwould imply an equivalent rate of release.
In practice, the articular clearance varies widely within each diag-
nostic group (Fig.1), the available data base is small, and it is generally
not useful to adjust concentrations on the basis of diagnosis alone. In
addition, the kinetics may be expected to change over time or with
therapy when serial concentrations are measured in any speciﬁc
knee. Our concerns relate to rates of release and rates demand serial,
well-timed observations of protein clearance rates. Fortunately, such
kinetic studies are straightforward. They clearly add an element of
complexity, but they will enhance the value of the data greatly.
Before addressing speciﬁc methodology, it is worthwhile to
review several principles of articular physiology: (1) Synovium,
menisci, and articular cartilage are the only tissues of concern in
the knee. Contributions from adjacent muscle, fat, etc. are trivial
and should not complicate SF data. (2) Unlike the linings of other
body cavities, the synovial surface is not mesothelial. Its lining
cells are loosely connected and are unsupported by an underlying
basement membrane. This means that the SF and the interstitial
ﬂuid (IF) form one continuous pool. (3) The draining lymphatics
are not size-selective. Therefore, the clearance of any globular
protein (with a molecular radius between w2 nm and w10 nm)ablished by Elsevier Ltd. All rights reserved.
Fig. 1. Rates of RISA clearance from knees of patients with RA are roughly double those
for OA, but note the wide variance within each group. Studied knees were selected
from patient subsets with chronic, clinical effusions. Thus, in particular, the OA group
does not include any of the many patients with this condition who do not have signif-
icant effusions (Adapted from ref.3).
Fig. 2. Clearance kinetics in an OA knee. External counting over the knee reveals that
free 123I (circles) leaves at a rapid rate consistent with diffusion across microvascular
fenestrae (t1/2 ¼ 58 min) while 131I labeled albumin (RISA, triangles) leaves more
slowly by convection through synovial lymphatics (t1/2 ¼ 1414 min). After early equil-
ibration between SF and tissue IF, the 131I radioactivity decline in SF aspirates (CPM/ml)
parallels the fall in external counts. The total volume (43 ml) did not change over the 3-
day period (From ref.3 with permission).
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plasma proteins. (4) Proteins within the joint are constrained by
a functionally impervious capsule that maintains a volume of SF
plus IF that remains steady during the course of a given kinetic
study, but may change greatly during the overall course of the
disease. (5) That space is accessible by needle without surgical
or general anesthetic intervention. (6) Essentially all physiologic
data are taken from the knee and extrapolation to other joints is
perilous.
These properties make the human knee an ideal site for studies
of microvascular physiology in health and of articular pathophysi-
ology in disease5. Work to date has shown that the concentration
relates in a linear manner to the molecular radius of almost all
plasma proteins. This fact permits one to use SF/S ratios for albumin
and for alpha2 macroglobulin as reference molecules to calculate
whether the SF/S ratio for a candidate protein of known molecular
radius is locally released5. Unfortunately, such a determination is
relative rather than quantitative and is therefore of limited value
for systematic studies.
In practice, radiolabelled human serum albumin (RISA) has
proved to be themost useful kinetic reference solute (Fig. 2). Sterile,
endotoxin-free RISA has been approved for human use and is avail-
able commercially. After blocking thyroidal uptake of any freedisotope with oral iodide, a well-calibrated tracer dose of RISA is
injected into the knee. At speciﬁc times, as infrequent as 1 and
24 h after the injection, the residual articular RISA is counted exter-
nally using appropriate care to attain the same counter position for
eachdetermination. The subject remainsambulatoryandmay return
to his or her home between counts. At the time of the ﬁnal count,
a sample of SF is withdrawn for any desired biochemical measures
and for external determination of the residual RISA concentration.
A sample of the original injectate is counted concurrently to permit
calculation of the total counts injected. Thus, the protocol requires
both a second visit and a second arthrocentesis, but the procedures
themselves are straightforward.
The logs of the external counts are then plotted against time to
determine a simple clearance constant in min1. The total of
injected counts is reduced to the counts remaining within the
knee at the time of aspiration (by subtracting the fraction shown
to have been cleared by the external plot), and that residual total
counts per minute (CPM) is divided by the CPM/ml in the ﬁnal
aliquot to yield the articular volume in ml. This volume (ml) is
then multiplied by the clearance constant (min1) to give the
lymphatic drainage rate (ml/min). That rate, in turn, may be multi-
plied by the concentration of the putative marker (mg/ml) to deter-
mine its removal in mg/min. When the effusions are chronic, we
can assume that each knee is in equilibrium at the time of study,
and the rate of removal will be equal to the rate of release into
the joint. Note that the clearance constant, in min1, is not the
same as the clearance, in ml/min. The constant itself can only be
used to compare release rates over time or between subjects if
the articular volumes are known to be the same (as they rarely are).
A detailed description of this methodology is provided in refer-
ence3. The technique can be employed in any knee containing sufﬁ-
cient SF to provide a sample to be counted at the conclusion of the
experiment6.
Thismethodcorrects for the inevitabledifferences in solute clear-
ance within or between knees. It was used effectively by Pitsillides
et al. to evaluate the effects of corticosteroid injections in swollen
RA and OA knees4, and I believe it is relevant to the assessment of
other therapeutic interventions. With respect to biomarkers, it was
used byMyers, O’Connor and Brandt in their model of canine osteo-
arthritis to show the marked differences in articular clearance that
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that a clearance-based approach is the only way to avoid the misin-
terpretations inherent in measures based on concentration alone7.
Again, however, I stress that this approach will be deﬁnitive only
for molecules in the range of molecular radii betweenw2 nm and
w10 nm. This is an important span since it includes the vastmajority
of plasma proteins, but it does not include many molecules of
interest to students of osteoarthritis. It may be applied, of course
for larger, i.e., hyaluronan or aggrecan fragments, and smaller, i.e.,
cytokine markers to indicate their rates of lymphatic removal, but
data regarding clearance of such molecules must be interpreted
cautiously with respect to the additional factors which may inﬂu-
ence their egress from joints.
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